Introduction
============

Recurrent spontaneous abortion (RSA), also referred to as recurrent miscarriage, habitual abortion or recurrent pregnancy loss, is defined by more than three consecutive miscarriages prior to 20 gestational weeks ([@b1-mmr-16-03-2367],[@b2-mmr-16-03-2367]). RSA occurs in 1--5% of women during pregnancy ([@b3-mmr-16-03-2367]). The cause of RSA remains unknown; thus, continuing clinical and laboratory investigations are required ([@b4-mmr-16-03-2367],[@b5-mmr-16-03-2367]). Previous studies have reported that various etiologic factors are involved in certain RSA cases; including chromosome abnormalities, endocrine diseases, uterine abnormalities, placental anomalies, hormonal problems, thrombophilia, infections, nutritional disorders, autoimmune disease and anatomy ([@b6-mmr-16-03-2367]--[@b8-mmr-16-03-2367]). The etiology of RSA remains to be fully elucidated despite numerous studies investigating the above factors. Early prediction of the potential risk of RSA is required to increase live birth rates in patients with RSA ([@b9-mmr-16-03-2367]).

Biomarkers are currently widely used to refine diagnoses, predict disease and monitor the effects of treatment ([@b10-mmr-16-03-2367]). It is established that the human proteome regulates cellular function and determines the phenotype; thus, the identification of relevant proteins is likely to reveal reliable biomarkers for predicting disease ([@b11-mmr-16-03-2367]). A range of potential biomarkers for RSA have been previously reported. Stortoni *et al* ([@b12-mmr-16-03-2367]) reported that expression levels of thrombomodulin were reduced by 45% in patients with RSA compared with healthy individuals, as determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Bao *et al* ([@b13-mmr-16-03-2367]) determined by RT-qPCR, western blot analysis and immunohistochemistry that serum Dickkopf-related protein (Dkk) 1 levels were increased in RSA patients compared with controls. Additional studies are required to validate these potential biomarkers and their prognostic value. Identifying novel RSA biomarkers may improve the diagnosis, safety and efficacy of current therapies for RSA. As one of the most intensely studied protein families in biomedical science, cytokines have been widely investigated as potential disease biomarkers ([@b14-mmr-16-03-2367]). The introduction of high-throughput and high-specificity detection of complex proteins at picomolar and femtomolar quantities, and antibody arrays, are now widely used for mining complex proteomes ([@b15-mmr-16-03-2367]), facilitating simultaneous screening of numerous secreted signal proteins in complex biological samples ([@b16-mmr-16-03-2367]). However, to the best of our knowledge, no previous study has identified serum RSA biomarkers using antibody array technology. Therefore, the present study used a RayBio^®^ Label-Based (L-Series) Human Antibody Array 1000 Membrane kit (RayBiotech, Inc., Norcross, GA, USA) to identify reliable biomarkers for the prediction of RSA.

Patients and methods
====================

### Patients and controls

From January 2014 to March 2015, a total of 60 Chinese patients with a history of RSA were recruited as the patient group from the Department of Traditional Chinese Medicine at the Beijing Obstetrics and Gynecology Hospital. They had normal endocrine levels, and their partners had normal spermatogenesis and sperm function. 'Blood stasis' syndrome (BSS, also known as *Xueyu zheng* in Chinese) is characterized in traditional medicine as 'pain that occurs in a fixed location, dark-purple face or tongue, bleeding, blood spots under the skin, and an astringent pulse' among other features ([@b17-mmr-16-03-2367]). The concept of blood stasis has been interpreted, changed and developed systematically since ancient times ([@b18-mmr-16-03-2367]). All 60 RSA patients exhibited the 'blood stasis' features described above at the time of study. Patient characteristics, including age at diagnosis, gravidities, number of child births and timing of spontaneous abortion, are summarized in [Table I](#tI-mmr-16-03-2367){ref-type="table"}. For the control group, 20 Chinese females who had experienced full-term pregnancies were recruited from the Department of Traditional Chinese Medicine at the Beijing Obstetrics and Gynecology Hospital.

### Ethical approval and sample collection

All participants signed informed consent forms prior to participation. The present study was approved by the Ethics Committee of the Beijing Obstetrics and Gynecology Hospital, Capital Medical University (Beijing, China; approval no. 2014-KY-001). Whole blood samples were collected from each participant. Serum was collected following blood centrifugation at 550 × g for 10 min at 4°C, and stored at −80°C. The sera of 23 RSA patients and 10 healthy subjects were pooled into 6 samples followed by standard processing ([@b19-mmr-16-03-2367]). The samples included those that could be classified as 'blood stasis' 1, 2 and 3, 'non-blood stasis' 1, 2, and 3, and controls 1--6. The order of mixing is presented in [Table II](#tII-mmr-16-03-2367){ref-type="table"}. All mixtures were obtained by mixing equal volumes of sera.

### Antibody array assay

The 12 samples described above were assayed for the relative expression of 1,000 human proteins. The target proteins included cytokines, chemokines, adipokines, growth factors, angiogenic factors, proteases, soluble receptors and soluble adhesion molecules. A RayBio^®^ Label-Based (L-Series) Human Antibody Array 1,000 Membrane kit (consisting of a combination of Human L-507 and L-493) was used for protein detection in accordance with the manufacturer\'s protocol. The signals were scanned at a wavelength of 532 nm using an InnoScan 300 Microarray Scanner (Innopsys, Carbonne, France; resolution, 10 µm) and analyzed using RayBio Analysis Tool software (AAH-BLG-1-SW and AAH-BLG-2-SW; RayBiotech, Inc.).

### Detection of protein levels by ELISA

As determined by microarray analysis, serum markers with significant differences in expression levels between patients and healthy individuals were detected in 60 patients and 20 controls using ELISA kits (ELH-TRAPPIN2, ELH-IGFBPRP1, ELH-RAGE, ELH-DKK3 and ELH-Angiopoietin-2; RayBiotech, Inc.) according to the manufacturer\'s protocol. Trappin-2, insulin-like growth factor-binding protein-related protein 1 (IGFBP-rp1)/IGFBP-7, receptor for advanced glycation end products (RAGE), Dkk3, and angiopoietin-2 levels were detected. Serum samples were incubated at room temperature. Following washing with wash buffer, a prepared biotinylated antibody was added into the microplate to capture the target protein. Following this, horseradish peroxidase-conjugated streptavidin was used to bind with biotin from the biotinylated antibody. Finally, 1-Step 3,3′,5,5′-tetramethylbenzidine-ELISA substrate solution was added followed by stop solution, and absorbance was measured at a wavelength of 450 nm by absorbance microplate reader ELx800 (BioTek Instruments, Inc., Winooski, VT, USA).

### Statistical analysis and bioinformatics

All array data analyses were performed using RayBio Analysis Tool software. Biostatistics and bioinformatics analysis included discriminatory protein analysis and data mining cluster analysis. Statistical differences between two groups were determined by Student\'s t-test. Fold change values of proteins were used as indicators of relative expression levels. Data mining cluster analysis was used to identify potential biomarkers by clustering all relevant proteins according to the similarity of their expression profiles using Cluster software version 3.0 (<http://cluster2.software.informer.com/3.0>). ELISA data was analyzed using SigmaPlot software version 12.0 (Systat Software, Inc., San Jose, CA, USA). T- and F-tests were used to analyze ELISA quantification. The receiver operating characteristics curve (ROC) method was used to assess sensitivity and specificity of potential biomarkers using SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Analysis of antibody microarrays

A total of 1,000 proteins were measured in the serum mixture using the microarray. The spectra of 1,000 proteins from eight samples are presented in [Fig. 1](#f1-mmr-16-03-2367){ref-type="fig"}. The results demonstrated that 151 proteins had significantly different expressions between the two groups. Of these differential proteins, eight were significantly upregulated, and 143 proteins were downregulated in RSA patients compared with controls ([Table III](#tIII-mmr-16-03-2367){ref-type="table"}). [Fig. 2](#f2-mmr-16-03-2367){ref-type="fig"} presents are boxplots of the fluorescence signal values of eight differential proteins, selected for signal strength, fold changes and clinical significance. Serum mixture samples were arranged by similarities in the abundance of these 151 markers in the sera clustering algorithm, which produced two clusters that contained patients and healthy individuals ([Fig. 3](#f3-mmr-16-03-2367){ref-type="fig"}).

### Validation of microarray data by ELISA

A total of five of the 151 proteins were selected for validation assay in 60 RSA and 20 control samples. Serum levels of trappin-2, IGFBP-rp1/IGFBP-7, RAGE, Dkk3 and angiopoietin-2 were selected to be measured by ELISA based on the results from the microarray experiments, previous reports on serum biomarkers in RSA and the availability of commercial test kits. Levels of IGFBP-rp1/IGFBP-7, Dkk3, RAGE and angiopoietin-2 were downregulated in RSA patients compared with healthy controls, which was consistent with the microarray results (P\<0.05; [Table IV](#tIV-mmr-16-03-2367){ref-type="table"} and [Fig. 4](#f4-mmr-16-03-2367){ref-type="fig"}).

### Analysis of sensitivity and specificity of serum biomarkers for RSA

To validate whether IGFBP-rp1/IGFBP-7, Dkk3, RAGE and angiopoietin-2 may be used as biomarkers for predicting RSA, ROC curves were used to analyze sensitivity and specificity. Area-under-ROC-curve values for IGFBP-rp1/IGFBP-7 ([Fig. 5A](#f5-mmr-16-03-2367){ref-type="fig"}), Dkk3 ([Fig. 5B](#f5-mmr-16-03-2367){ref-type="fig"}), RAGE ([Fig. 5C](#f5-mmr-16-03-2367){ref-type="fig"}) and angiopoietin-2 ([Fig. 5D](#f5-mmr-16-03-2367){ref-type="fig"}) cytokines were 0.881, 0.823, 0.79 and 0.814, respectively. IGFBP-rp1/IGFBP-7 had a sensitivity of 95% and specificity of 78.33%. Dkk3 had a sensitivity of 80% and specificity of 83.33%. RAGE had a sensitivity of 65% and specificity of 86.70%. Angiopoietin-2 had a sensitivity of 90% and specificity of 64.40%. All these were deemed suitable biomarkers for the prediction of RSA.

Discussion
==========

Potential biomarkers of RSA have previously been reported. Khonina *et al* ([@b20-mmr-16-03-2367]) investigated whether mixed lymphocyte reaction blocking factor may be used as an indicator of the efficacy for immunotherapy with paternal lymphocytes in females with RSA. Metwally *et al* ([@b21-mmr-16-03-2367]) performed a proteomic analysis of obese and overweight women with RSA by 2-D gel electrophoresis, principle component analysis and mass spectrometry, and demonstrated that RSA patients exhibit a significant increase in haptoglobin expression. Ibrahim *et al* ([@b22-mmr-16-03-2367]) demonstrated that pentraxin-3 indicates the presence of abnormally exaggerated intrauterine inflammation that may cause pregnancy failure in females with unexplained RSA. Kim *et al* ([@b23-mmr-16-03-2367]) identified RSA-associated factors in human blood samples by 2-D gel electrophoresis, and analyzed spots samples with matrix-assisted laser desorption/ionization-time of flight/mass spectrometry, and reported that in RSA patients, inter-α-trypsin inhibitor heavy chain family member 4 (ITI-H4) expression was low and exhibited a molecular weight of 120 kDa in controls; however, ITI-H4 was expressed at higher levels and at a modified molecular weight of 36 kDa in the RSA patient group. This indicated that ITI-H4 may be used as biomarker of RSA.

The present study used antibody array technology for a primary screening of RSA biomarkers on pooled samples. The array results revealed that the levels of eight cytokines were significantly increased in the RSA patient group compared with controls, and the levels of 143 of the tested 1,000 proteins were significantly reduced in the RSA patient group compared with controls. A total of 5 proteins, trappin-2, IGFBP-rp1/IGFBP-7, Dkk3, RAGE and angiopoietin-2, were selected for ELISA validation assay in a larger cohort of patient and control subjects. ELISA results for these proteins were in accordance with the array results. Sensitivity and specificity analysis by ROC revealed that these four cytokines may be used as biomarkers of RSA.

To the best of our knowledge, the association between IGFBP-rp1/IGFBP-7, Dkk3 and angiopoietin-2, and RSA has not been reported. However, an isoform of the RAGE protein, sRAGE, has been reported to be associated with RSA ([@b24-mmr-16-03-2367]).

IGFBP-rp1/IGFBP-7
=================

IGFs, which have characteristics of tissue growth factors and circulating growth hormones, are potent mitogens and anti-apoptotic agents ([@b25-mmr-16-03-2367]). IGFs include the hormones IGF-I and -II and their corresponding receptors, and the IGFBPs ([@b26-mmr-16-03-2367]). The IGFBP superfamily includes six members (IGFBP-1-6) and 10 associated proteins (IGFBP-rp1-10) ([@b27-mmr-16-03-2367]). IGFBP-7 has been demonstrated to be a tumor suppressor in a variety of cancers. Benatar *et al* ([@b28-mmr-16-03-2367]) reported that treatment with IGFBP-7 may have therapeutic potential for triple-negative breast cancer. Liu *et al* ([@b29-mmr-16-03-2367]) demonstrated that IGFBP-7 was downregulated in gastric cancer, and that it may be used as an indicator of poor prognosis in patients with gastric cancer. IGFBP-7 has additionally been proposed as a novel biomarker for assessing the risk of acute kidney injury ([@b30-mmr-16-03-2367]) and heart failure with reduced ejection fraction, and has been demonstrated to have links to the presence and severity of echocardiographic parameters of abnormal diastolic function ([@b31-mmr-16-03-2367]).

Dkk3
====

The Wnts are an evolutionarily conserved family of secreted glycoproteins characterized by numerous conserved cysteine residues ([@b32-mmr-16-03-2367]). The Dkk proteins are secreted Wnt inhibitors, inducing removal of the Wnt co-receptor low-density lipoprotein receptor-related protein, and consist of four primary members in vertebrates (Dkk1-4) ([@b33-mmr-16-03-2367],[@b34-mmr-16-03-2367]). Dkk-3 is downregulated in various types of cancer cells. Loss of Dkk3 protein expression is associated with poor prognoses in patients with gastric cancer, indicating that it may be a biomarker for predicting lymph node involvement in these patients ([@b35-mmr-16-03-2367]). Dkk3 has recently been implicated in clear cell renal cell carcinoma, and may present a novel molecular target for its diagnosis and treatment ([@b36-mmr-16-03-2367]). Additionally, Dkk3 may represent a therapeutic target for the treatment of heart failure following myocardial infarction ([@b37-mmr-16-03-2367]).

RAGE
====

RAGE is a cell-surface receptor that interacts with AGEs, and is a member of the immunoglobulin superfamily ([@b38-mmr-16-03-2367]). RAGE activation via its multiple ligands, including S100 calcium-binding protein (S100A) 4 ([@b39-mmr-16-03-2367]), high mobility group box 1 protein ([@b40-mmr-16-03-2367]) and amyloid-β protein ([@b41-mmr-16-03-2367]), serves important roles in certain diseases. Dahlmann *et al* ([@b42-mmr-16-03-2367]) demonstrated that the activity of S100A4-RAGE induces RAGE-dependent increases in the migratory and invasive capabilities of colorectal cancer cells. Guo *et al* ([@b43-mmr-16-03-2367]) identified RAGE as a potential prognostic biomarker in renal cell carcinoma. RAGE/S100A7 signaling has been demonstrated to have a functional role in linking inflammation to aggressive breast cancer development; therefore, RAGE expression is currently regarded as a potential biomarker for triple-negative breast cancer ([@b44-mmr-16-03-2367]). Additionally, overexpression of RAGE may be a useful marker to predict gastric cancer progression ([@b45-mmr-16-03-2367]).

Angiopoietin-2
==============

As a member of the angiopoietin family, angiopoietin-2 has complex and unique roles in regulating angiogenesis, and has additional unconventional functions, including stimulating tumor angiogenesis, invasion and metastasis via Tie2-independent signaling pathways, involving integrin-mediated signaling. Therefore, angiopoietin-2 may have great potential as a therapeutic target, prognostic marker and inhibitor of human cancer ([@b46-mmr-16-03-2367]). Angiopoietin-2 is expressed during vascular remodeling, thus preventing vascular stability ([@b47-mmr-16-03-2367]). A study by Morrissey *et al* ([@b48-mmr-16-03-2367]) demonstrated that angiopoietin-2 inhibition impeded tumor growth of LuCaP 23.1 prostate cancer xenografts, and suggested that angiopoietin-2 inhibition in combination with other treatments is a potential therapy for metastatic disease patients. Calfee *et al* ([@b49-mmr-16-03-2367]) reported that lowering plasma angiopoietin-2 with fluid conservative therapy may be beneficial, in part by decreasing endothelial inflammation. Goede *et al* ([@b50-mmr-16-03-2367]) demonstrated that serum angiopoietin-2 represents a candidate biomarker for the outcome of metastatic colorectal cancer patients treated with bevacizumab-containing therapy. Additionally, angiopoietin-2 has been associated with other diseases, including chronic kidney disease ([@b51-mmr-16-03-2367]) and cerebral malaria ([@b52-mmr-16-03-2367]).

In conclusion, the present study used a microarray platform to detect 1,000 proteins to identify dysregulated serum factors in RSA samples. This method was demonstrated to be effective in investigating dynamic alterations in protein profiles, and to select target proteins for further RSA research. The results indicated that IGFBP-rp1/IGFBP-7, Dkk3, RAGE and angiopoietin-2 expression were downregulated in RSA patients, suggesting that they may be important in the pathological process of RSA. Furthermore, upregulating them may inhibit the development of RSA. Therefore, these biomarkers represent potential predictive and diagnostic markers for RSA due to their high sensitivity and specificity. However, larger-scale studies are required to confirm the diagnostic value of these markers.
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![Protein spectra from RayBio L-Series Human 507 (507 proteins) and 493 (493 proteins) antibody arrays. Representative images from human antibody arrays demonstrating the reactivity of pooled serum samples to arrays L series (1,000 proteins) in healthy controls and RSA patients. Each protein was measured in duplicate. A total of eight of significantly different factors on the microarrays are marked in elliptical boxes. IGFBP-rp1/IGFBP-7, insulin-like growth factor-binding protein-related protein 1/insulin-like growth factor-binding protein 7; Dkk3, Dickkopf-related protein 3; RAGE, receptor for advanced glycation end products; RSA, recurrent spontaneous abortion; TOPORS, topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein ligase; C2, complement C2; RECK, reversion-inducing-cysteine rich protein with kazal motifs.](MMR-16-03-2367-g00){#f1-mmr-16-03-2367}

![Boxplots of differential serum proteins between RSA patients and controls. P\<0.05, RSA vs. control for all presented proteins. ANG-2, angiopoietin 2; IGFBP-rp1/IGFBP-7, insulin-like growth factor-binding protein-related protein 1/insulin-like growth factor-binding protein 7; Dkk3, Dickkopf-related protein 3; RAGE, receptor for advanced glycation end products; RSA, recurrent spontaneous abortion; TOPORS, topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein ligase; C2, complement C2; RECK, reversion-inducing-cysteine rich protein with kazal motifs.](MMR-16-03-2367-g01){#f2-mmr-16-03-2367}

![Cluster map of protein expression levels of the 151 proteins in 12 mixed serum samples. The signal values of the 151 proteins from microarray analyses were used to prepare the cluster map. Red shades indicate higher expression levels, green shades indicate lower expression levels, and black shades indicate median expression levels.](MMR-16-03-2367-g02){#f3-mmr-16-03-2367}

![Validation of five differentially expressed proteins obtained from microarray analysis, and validated by ELISA. Concentrations of these factors in serum samples obtained from RSA patients and healthy controls were calculated using the four parameters method. IGFBP-rp1/IGFBP-7, insulin-like growth factor-binding protein-related protein 1/insulin-like growth factor-binding protein 7; Dkk3, Dickkopf-related protein 3; RAGE, receptor for advanced glycation end products; RSA, recurrent spontaneous abortion.](MMR-16-03-2367-g03){#f4-mmr-16-03-2367}

![ROC curve analysis for the four upregulated serum cytokines as validated by ELISA. The area under the ROC curve (AUC) indicates the mean sensitivity of the biomarkers (A) IGFBP-rp1, (B) Dkk3, (C) RAGE and (D) angiopoietin-2 ([Fig. 5D](#f5-mmr-16-03-2367){ref-type="fig"}). 0.5≤AUC≤1, the biomarker is strongly differential between patients and controls; AUC≤0.5, no predictive value. ROC, receiver operating characteristics curve; IGFBP-rp1/IGFBP-7, insulin-like growth factor-binding protein-related protein 1/insulin-like growth factor-binding protein 7; Dkk3, Dickkopf-related protein 3; RAGE, receptor for advanced glycation end products; RSA, recurrent spontaneous abortion.](MMR-16-03-2367-g04){#f5-mmr-16-03-2367}

###### 

Characteristics of 60 patients with recurrent spontaneous abortion.

  Characteristic                                                          Value
  ----------------------------------------------------------------------- ----------
  Age at diagnosis^[a](#tfn1-mmr-16-03-2367){ref-type="table-fn"}^        30±2.8
  Gravidities^[a](#tfn1-mmr-16-03-2367){ref-type="table-fn"}^             3±0.5
  No. of childbirths                                                      
    1^[b](#tfn2-mmr-16-03-2367){ref-type="table-fn"}^                     5 (8%)
    0^[b](#tfn2-mmr-16-03-2367){ref-type="table-fn"}^                     55 (92%)
  Spontaneous abortions^[a](#tfn1-mmr-16-03-2367){ref-type="table-fn"}^   3±0.5
    2^[b](#tfn2-mmr-16-03-2367){ref-type="table-fn"}^                     1 (2%)
    1^[b](#tfn2-mmr-16-03-2367){ref-type="table-fn"}^                     12 (20%)
    0^[b](#tfn2-mmr-16-03-2367){ref-type="table-fn"}^                     47 (78%)

Data are expressed as the mean ± standard deviation.

Data are expressed as the number of patients (% of total).

###### 

Pooling of serum samples.

  Pooled serum sample                           Original sample
  --------------------------------------------- -------------------
  Patients with RSA                             
    Blood stasis group 1 (thrombus 1)           A1, A2, A3, A4
    Blood stasis group 2 (thrombus 2)           A5, A6, A7, A8
    Blood stasis group 3 (thrombus 3)           A9, A10, A11, A12
    Non-blood stasis group 1 (non-thrombus 1)   C1, C2, C3, C4
    Non-blood stasis group 2 (non-thrombus 2)   C5, C6, C7, C8
    Non-blood stasis group 3 (non-thrombus 3)   C9, C10, C11
  Control                                       
    1                                           E1, E2, E3
    2                                           E4, E5, E6
    3                                           E7
    4                                           E8
    5                                           E9
    6                                           E10

RSA, recurrent spontaneous abortion.

###### 

A total of 151 proteins with significantly different expression levels between patients with RSA and controls.

                            RSA           Control      RSA vs. control                                
  ------------------------- ------------- ------------ ----------------- ------------ ------- ------- -------
  A2M                       4,650.558     373.053      6,374.645         269.687      0.494   0.000   0.730
  ADAMTS-10                 7,862.456     1,306.692    13,925.383        550.378      0.081   0.000   0.565
  ADAMTS-15                 2,999.115     479.112      5,705.655         1,924.875    0.008   0.017   0.526
  ADAMTS-5                  558.209       250.695      1,466.103         483.403      0.176   0.002   0.381
  ADAMTS-L2                 20,775.755    2,676.424    27,565.213        1,305.789    0.141   0.000   0.754
  ALK                       7,976.603     1,428.122    13,199.048        2,632.151    0.206   0.002   0.604
  Angiopoietin-2            20,789.029    4,292.976    48,570.398        4,977.529    0.753   0.000   0.428
  ApoC2                     14,305.316    2,066.666    19,754.508        2,309.965    0.813   0.002   0.724
  ApoH                      4,898.886     462.884      7,760.884         1,065.437    0.091   0.000   0.631
  ApoM                      1,502.749     273.114      3,924.876         654.067      0.078   0.000   0.383
  APP                       12,633.899    1,318.521    19,428.245        5,101.616    0.010   0.021   0.650
  Axl                       1,510.055     1,117.320    4,936.198         495.598      0.099   0.000   0.306
  BAF57                     1,181.342     265.140      1,906.967         361.301      0.513   0.003   0.619
  BAFF R/TNFRSF13C          130.169       152.078      1,362.334         162.415      0.889   0.000   0.096
  Bax                       15,217.862    3,242.826    38,315.362        7,712.389    0.080   0.000   0.397
  BDNF                      13,455.044    6,688.395    25,250.436        5,906.534    0.792   0.009   0.533
  β 2M                      1,320.861     133.263      1,910.310         294.761      0.106   0.001   0.691
  BIK                       311.407       134.485      1,179.513         269.458      0.153   0.000   0.264
  BMP-3                     10,702.264    3,851.243    28,110.700        15,617.736   0.008   0.041   0.381
  BMP-3b/GDF-10             124.436       41.431       347.417           122.473      0.033   0.005   0.358
  BMP-4                     901.991       2,56.578     1,767.609         343.897      0.536   0.001   0.510
  BMPR-IB/ALK-6             23,780.461    9648.386     62,589.402        6,422.893    0.393   0.000   0.380
  BTC                       11,944.615    4,921.916    21,760.107        3,620.813    0.517   0.003   0.549
  C2                        22,604.021    2,719.955    29,647.219        2,700.060    0.988   0.001   0.762
  C5/C5a                    12,737.991    1,525.086    22,749.974        7,304.236    0.004   0.019   0.560
  Calsyntenin-1             1,911.570     607.215      4,505.218         691.477      0.782   0.000   0.424
  CD40/TNFRSF5              1,101.031     337.593      3,397.425         678.353      0.152   0.000   0.324
  Chordin-Like 1            1,391.942     585.338      3,128.589         566.356      0.944   0.000   0.445
  CNTF R α                  77,532.324    10,164.182   114,914.734       12,924.497   0.611   0.000   0.675
  Contactin-1               3,977.884     438.734      6,093.532         1,458.926    0.020   0.015   0.653
  Cripto-1                  8,176.343     2,831.476    18,724.736        4,786.781    0.274   0.001   0.437
  CRTH-2                    34,856.201    6,547.851    55,742.907        8,503.753    0.580   0.001   0.625
  CXCR4 (fusin)             3,702.606     1,090.358    11,095.207        6,134.514    0.002   0.031   0.334
  Dkk-3                     14,387.266    3,452.455    31,716.357        11,437.946   0.020   0.012   0.454
  DLL4                      1,759.891     629.238      3,330.977         898.310      0.453   0.006   0.528
  EDAR                      1,240.627     223.958      4,773.756         1,971.378    0.000   0.007   0.260
  EGF R/ErbB1               11,026.167    1,733.072    15,758.956        2,371.519    0.508   0.003   0.700
  EG-VEGF/PK1               29,916.922    4,877.762    51,349.446        16,211.012   0.020   0.022   0.583
  EMAP-II                   10,666.342    2,600.714    19,708.795        3,896.837    0.395   0.001   0.541
  EphB4                     1,962.256     406.898      5,161.814         945.891      0.088   0.000   0.380
  ErbB2                     4,267.172     1,130.288    15,536.343        9,241.970    0.000   0.030   0.275
  ESAM                      2,854.186     495.592      5,990.106         2,581.532    0.002   0.030   0.476
  FAM3B                     1,270.946     447.324      4,455.137         885.200      0.160   0.000   0.285
  FGF R4                    3,992.796     1,049.190    12,794.810        7,288.004    0.001   0.031   0.312
  FGF R5                    2,826.176     1,013.809    7,878.562         1,003.601    0.983   0.000   0.359
  FGF-19                    1,641.777     369.438      4,442.636         778.147      0.128   0.000   0.370
  FGF-9                     6,413.361     1,443.488    22,180.535        5,185.520    0.014   0.000   0.289
  FGFR1                     11,978.622    1,527.435    16,683.655        4,343.023    0.039   0.045   0.718
  FGFR2                     13,703.293    2,914.828    23,307.209        7,653.038    0.054   0.017   0.588
  Ficolin-3                 3,374.750     486.123      8,120.462         4,212.321    0.000   0.040   0.416
  Follistatin-like1         2,481.289     721.297      7,152.976         1,161.224    0.319   0.000   0.347
  Galectin-1                1,435.877     634.069      3,694.218         803.285      0.616   0.000   0.389
  Galectin-3BP              10,655.461    1,406.056    13,522.242        1,910.307    0.517   0.014   0.788
  Gas1                      4,530.505     1,493.529    7,110.508         1,228.339    0.678   0.008   0.637
  GASP-1/WFIKKNRP           85,406.876    7,073.932    128,207.327       24,054.577   0.018   0.006   0.666
  GATA-3                    7,625.978     591.277      13,276.727        2,655.282    0.005   0.003   0.574
  GCP-2/CXCL6               847.677       514.092      2,243.977         1,012.301    0.163   0.013   0.378
  GLO-1                     997.491       290.387      2,106.667         501.997      0.255   0.001   0.473
  Glucagon                  61,025.896    9,853.803    128,506.268       35,031.652   0.015   0.004   0.475
  GluT2                     11,546.660    704.259      37,514.070        2,261.457    0.023   0.000   0.308
  Glypican 3                1,389.140     249.379      2,554.322         649.947      0.056   0.002   0.544
  Glypican 5                15,529.644    2,266.574    25,519.026        7,257.053    0.023   0.018   0.609
  GPX1                      2,008.854     557.930      4,383.148         782.893      0.475   0.000   0.458
  GPX3                      3,009.541     1,283.488    5,083.531         927.399      0.493   0.009   0.592
  GRP78                     2,266.940     302.999      4,387.312         1,150.085    0.011   0.005   0.517
  Hemopexin                 725.265       151.625      3,871.951         913.350      0.001   0.000   0.187
  HRG-α                     5,321.121     1,385.473    7,078.008         834.906      0.291   0.024   0.752
  HSP10                     26,971.939    3,802.952    43,781.370        10,058.305   0.052   0.003   0.616
  I-309                     4,283.951     2,116.728    13,856.485        3,913.389    0.204   0.000   0.309
  IBSP                      7,712.034     986.133      10,133.874        1,761.061    0.229   0.015   0.761
  IGFBP-4                   1,453.473     684.730      4,146.757         1,511.595    0.107   0.003   0.351
  IGFBP-rp1/IGFBP-7         7,523.924     2,135.058    16,380.247        2,502.068    0.736   0.000   0.459
  IGF-II                    65,869.138    5,912.640    94,321.230        10,392.485   0.241   0.000   0.698
  IL-1 ra                   361,872.941   34,398.268   563,878.996       45,414.321   0.011   0.011   0.642
  IL-13 R α1                6,360.695     1,012.833    24,083.997        13,484.474   0.000   0.023   0.264
  IL-17C                    2,345.533     541.033      7,048.395         748.914      0.493   0.000   0.333
  IL-18 R β/AcPL            1,935.580     858.981      5,832.686         1,358.705    0.337   0.000   0.332
  IL-29                     8,733.803     1,800.279    24,866.993        5,813.232    0.022   0.001   0.351
  IL-31                     1,970.735     687.942      5,958.295         784.836      0.779   0.000   0.331
  IL-31 RA                  1,182.894     372.281      3,207.266         506.214      0.516   0.000   0.369
  IL-33                     2,441.589     430.891      3,847.273         1,061.515    0.070   0.013   0.635
  IL-6 R                    3,540.308     909.773      6,566.421         1,881.755    0.137   0.005   0.539
  IL-8                      25,002.761    6,204.334    34,829.214        6,706.528    0.869   0.025   0.718
  Kallikrein 14             2,979.489     615.746      5,825.747         1,585.646    0.058   0.002   0.511
  LBP                       3,409.164     463.893      13,342.910        8,052.946    0.000   0.029   0.256
  LIF R α                   13,797.957    2,293.325    27,604.197        8,923.296    0.010   0.012   0.500
  LIF                       332.827       242.463      1,628.345         875.661      0.014   0.014   0.204
  LIGHT/TNFSF14             2,092.869     917.268      6,360.354         1,227.569    0.538   0.000   0.329
  Lipocalin-1               20,832.310    4,151.253    34,570.502        9,172.736    0.107   0.007   0.603
  Livin                     2,707.067     795.904      4,194.195         745.424      0.889   0.007   0.645
  LRG1                      11,113.403    863.592      28,581.729        14,531.460   0.000   0.032   0.389
  Lymphotoxin β R/TNFRSF3   788.596       380.913      3,291.572         764.370      0.153   0.000   0.240
  M-CSF                     28,394.735    5,351.774    41,766.017        11,016.348   0.139   0.023   0.680
  Midkine                   3,267.246     433.600      5,032.121         1,617.032    0.012   0.044   0.649
  MIF                       3,951.056     885.814      6,986.334         1,120.792    0.618   0.000   0.566
  MIP-1α                    50,222.493    12,359.813   94,756.426        25,311.008   0.142   0.003   0.530
  MMP-11/Stromelysin-3      54,153.970    12,843.620   69,764.345        7,386.564    0.250   0.027   0.776
  MMP-16/MT3-MMP            11,330.829    2,524.054    26,764.023        11,916.806   0.004   0.024   0.423
  MMP-8                     52,067.139    3,933.472    70,211.908        7,728.075    0.165   0.000   0.742
  MSP α Chain               13,201.992    2,412.896    25,409.389        4,525.441    0.194   0.000   0.520
  NEP                       1,581.827     658.480      3,958.249         666.439      0.980   0.000   0.400
  NM23-H1/H2                550.675       189.223      2,651.125         1,022.967    0.002   0.004   0.208
  Orexin B                  43,718.747    7,996.118    74,138.593        18,347.514   0.092   0.004   0.590
  Osteoactivin/GPNMB        2,895.689     312.735      5,540.870         1,872.568    0.001   0.017   0.523
  PD-1                      2,591.490     389.734      4,141.350         1,038.516    0.051   0.007   0.626
  PDGF-C                    9,264.920     2,881.398    24,377.899        9,157.178    0.024   0.008   0.380
  PDGF-D                    2,883.630     396.751      5,130.131         907.360      0.093   0.000   0.562
  PDX-1                     2,270.140     363.742      3,981.057         824.869      0.097   0.001   0.570
  PEPSINOGEN I              2,439.074     824.492      6,093.801         1,335.963    0.313   0.000   0.400
  Persephin                 2,515.448     1,011.303    4,523.807         838.775      0.691   0.004   0.556
  PGRP-S                    12,316.910    730.024      16,966.564        1,180.649    0.315   0.000   0.726
  PIM2                      1,865.699     437.191      4,879.191         1,260.593    0.036   0.001   0.382
  PKM2                      2,655.795     1,099.697    4,528.436         478.749      0.092   0.003   0.586
  RAGE                      9,020.357     1,947.254    25,325.305        10,739.884   0.002   0.013   0.356
  RANK/TNFRSF11A            2,020.058     587.942      4,020.679         833.497      0.462   0.001   0.502
  RECK                      5,084.724     891.920      11,081.323        3,186.035    0.014   0.005   0.459
  RELT/TNFRSF19L            31,871.125    4,886.989    61,866.224        17,568.797   0.014   0.007   0.515
  ROBO4                     66,732.387    11,925.740   100,118.428       17,349.652   0.430   0.003   0.667
  S100A10                   1,189.482     653.171      4,146.007         336.156      0.171   0.000   0.287
  S100A4                    4,024.174     328.979      5,366.717         482.437      0.421   0.000   0.750
  S100A6                    3,485.252     541.367      6,023.360         1,041.092    0.178   0.000   0.579
  Serpin A8                 1,755.946     304.447      3,270.617         704.644      0.089   0.001   0.537
  Serpin A9                 1,258.179     327.453      2,710.239         999.220      0.029   0.015   0.464
  Smad 1                    1,028.273     540.825      3,720.431         748.020      0.494   0.000   0.276
  Smad 7                    34,565.690    2,075.517    55,551.432        18,891.474   0.000   0.042   0.622
  Smad 8                    6,886.663     2,599.832    15,373.512        4,688.229    0.221   0.003   0.448
  SOST                      3,117.271     461.906      6,218.660         1,701.605    0.012   0.006   0.501
  Spinesin                  20,626.782    4,848.625    38,828.941        4,444.642    0.853   0.000   0.531
  Syndecan-1                1,772.888     379.277      3,778.232         1,215.352    0.023   0.008   0.469
  Thrombospondin-4          10,921.569    2,002.073    23,198.652        9,994.362    0.003   0.029   0.471
  TIM-1                     2,132.294     259.727      4,438.018         697.608      0.049   0.000   0.480
  TIMP-3                    4,008.775     1,259.727    6,988.724         1,853.036    0.417   0.009   0.574
  TRADD                     127,030.588   28,309.796   222,266.652       75,285.718   0.051   0.016   0.572
  TRAIL R2/DR5/TNFRSF10B    17,190.463    4,094.960    32,861.735        13,104.866   0.023   0.032   0.523
  Trappin-2                 5,865.048     978.164      19,388.585        11,625.715   0.000   0.036   0.303
  TROY/TNFRSF19             2,324.349     786.973      5,012.391         1,945.216    0.069   0.011   0.464
  TRPC1                     2,436.721     681.450      6,693.017         2,511.517    0.012   0.008   0.364
  TSLP                      1,853.969     303.884      5,110.938         2,119.578    0.001   0.013   0.363
  TSLP R                    1,905.470     965.346      6,488.242         1,625.517    0.277   0.000   0.294
  Ubiquitin+1               17,529.029    5,002.370    34,561.192        16,122.797   0.023   0.049   0.507
  uPA                       52,463.526    6,879.542    94,616.706        25,331.681   0.012   0.008   0.554
  VEGF-D                    24,467.055    5,668.534    52,501.169        6,836.652    0.691   0.000   0.466
  WISP-1/CCN4               2,330.112     1,166.842    5,516.779         2,727.490    0.086   0.025   0.422
  GASP-2/WFIKKN             71,246.693    3,344.127    31,422.325        19,817.529   0.001   0.004   2.267
  IL-1 F5/FIL1δ             30,158.276    6,083.967    13,083.494        8,056.469    0.553   0.002   2.305
  IL-28A                    71,058.941    7,420.008    30,883.742        18,108.416   0.072   0.001   2.301
  Kallikrein 6              18,588.432    1,695.500    10,786.937        3,766.885    0.104   0.001   1.723
  NGF R                     42,876.389    1,905.084    1,8740.985        13,128.177   0.001   0.006   2.288
  NrCAM                     73,805.167    6,435.403    5,1415.054        8,782.973    0.511   0.001   1.435
  TOPORS                    49,264.099    3,557.276    3,4240.228        8,383.960    0.083   0.002   1.439
  VEGF R2 (KDR)             37,152.074    4,541.513    1,2904.085        9,743.845    0.119   0.000   2.879

SD, standard deviation; RSA, recurrent spontaneous abortion.

###### 

ELISA analysis of cytokine levels in the serum of patients with RSA and healthy controls.

                                                      Patients vs. control                                                           
  ------------------- --------------- --------------- ---------------------- ------------------------------------------------------- -------
  Trappin-2           429.17±125.17   453.26±132.34   0.718                  0.473                                                   0.947
  IGFBP-rp1/IGFBP-7     86.94±16.49   115.63±20.12    0.246                  0.000^[a](#tfn5-mmr-16-03-2367){ref-type="table-fn"}^   0.752
  RAGE                  91.29±44.28   163.64±76.99    0.001                  0.001^[a](#tfn5-mmr-16-03-2367){ref-type="table-fn"}^   0.558
  Dkk3                  28.16±6.22      38.96±10.05   0.005                  0.000                                                   0.723
  Angiopoietin-2      461.34±484.38   887.72±576.22   0.312                  0.002^[a](#tfn5-mmr-16-03-2367){ref-type="table-fn"}^   0.520

P\<0.05, RSA vs. control. Data are expressed as the mean ± standard deviation. IGFBP-rp1/IGFBP-7, insulin-like growth factor-binding protein-related protein 1/insulin-like growth factor-binding protein 7; Dkk3, Dickkopf-related protein 3; RAGE, receptor for advanced glycation end products; RSA, recurrent spontaneous abortion.
